

ASX ANNOUNCEMENT

SIMAVITA COMPLETES FURTHER \$100K FINANCING TO SUPPORT KEY COMMERCIAL ACTIVITIES

For Immediate Release:

20 November 2018

Sydney, Australia – Simavita Limited [ASX: SVA] today announced that it had completed a \$100,000 financing. This was achieved by a private placement for \$100,000 (**Placement**) and is in addition to the financing announced on 3 October 2018 of \$1.975 million and the further \$1 million by way of a convertible note (subject to approval from shareholders at the 2018 Annual General Meeting) [collectively, **October Fundraising**].

Proceeds of the Placement will be used by the Company towards working capital and key commercialization activities specifically focused on major markets in North America and Europe.

Key terms of the Private Placement

- A Placement of 3,333,331 CDIs for aggregate subscriptions of \$100,000 with sophisticated investors at an offer price of \$0.03 per new CDI. None of the investors who will be issued CDIs are related parties of the Company.
- The Offer Price of \$0.03 per new CDI represents a premium of approximately 3% to the last closing price of \$0.029 on 19 November 2018 and a discount of 9% to the 15 day VWAP. This discount to the 15 day VWAP is in compliance with the pricing requirements set out in Listing Rule 7.1A.
- 3,333,331 new Simavita CDIs will be issued under the Placement, which is 0.8% of the total number of CDIs currently on issue (414,444,801). The new CDIs will rank equally with existing CDIs. Settlement occurred on 19 November 2018 and the CDIs will be issued and quoted on the ASX on 20 November 2018.
- Under the terms of the Convertible Note announced to the market on 3 October 2018, the noteholder, at their option, may (but is not obliged to) reduce their investment of \$1,000,000 by the amount of this Placement.
- There are no underwriting arrangements in place for the Placement. Fees and costs incurred in connection with the issue are approximately \$5,000.
- No shareholder approval is required for the issue of CDIs under the Placement as Simavita's existing placement capacity under ASX Listing Rule 7.1A, approved at the 2017 Annual General Meeting will be used.
- Existing holders of CDIs will be diluted by 0.79% as a result of the Placement (and approximately 8.12% after allowing for the issue of the CDIs represented by the October Fundraising).
- The Board considered a Placement as the best method for raising funds in the time frame required and to achieve funding certainty.

For further information, please check our website (www.simavita.com) or contact:

Ms Peta Jurd
E: pjurd@simavita.com
T: +61 421 466 653

About Simavita

Simavita (ASX: SVA) develops and markets advanced systems associated with smart, wearable and disposable sensors for the global diaper manufacturing industry and also for the aged and disabled care markets. This industry currently generates approximately USD 64bn in annual revenues.

Simavita offers an extremely low cost sensor platform technology for everyday use in all adult and infant diapers. AlertPLUS™ is incorporated into the diaper manufacturing process and connects to your smart device via an App. The platform is ready for partnering with major international diaper manufacturers.

Simavita's technology portfolio also includes AssessPLUS™, an easy to use tablet based product for the assessment of incontinence which delivers a personalised, evidence base incontinence care plan.

With the support of our shareholders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. www.simavita.com